[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Abderrahim E, Jbali H, Ounissi M, Hedri H, Bakir S, Ben Abdallah T, Ben Maïz H, Kheder A: [Association of disseminated nocardiosis and Kaposi's sarcoma after kidney transplantation]. Rev Med Interne; 2009 May;30(5):446-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of disseminated nocardiosis and Kaposi's sarcoma after kidney transplantation].
  • [Transliterated title] Nocardiose disséminée associée à un sarcome de Kaposi après transplantation rénale.
  • We report a 40-year-old kidney recipient who developed disseminated nocardiosis associated with cutaneous Kaposi's sarcoma.
  • The withdrawal of immunosuppressive therapy and prolonged antibiotic therapy, including imipenem and trimethoprim-sulfamethoxazole, resulted in a favourable outcome of both disorders.
  • Three years later, graft function remains stable with a complete regression of skin and pulmonary abnormalities.
  • This case report illustrates the predisposing role of immunosuppressive treatment in the occurrence of infectious and neoplastic complications observed after solid-organ transplantation.

  • Genetic Alliance. consumer health - Nocardiosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. TRIMETHOPRIM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926605.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents, Urinary; 0 / Immunosuppressive Agents; 71OTZ9ZE0A / Imipenem; AN164J8Y0X / Trimethoprim
  •  go-up   go-down


2. van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, Mhango B, Hartung T, Phiri S, Hosseinipour MC: Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health; 2009 Aug;14(8):856-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.
  • OBJECTIVES: In antiretroviral therapy (ART) scale-up programmes in sub-Saharan Africa viral load monitoring is not recommended.
  • We wanted to study the impact of only using clinical and immunological monitoring on the diagnosis of virological ART failure under routine circumstances.
  • Active tuberculosis and Kaposi's sarcoma were the most common conditions causing misclassification of virological ART failure.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Drug Resistance, Viral. HIV Infections / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Female. Humans. Malawi. Male. Middle Aged. Practice Guidelines as Topic. Sarcoma, Kaposi / diagnosis. Treatment Failure. Tuberculosis, Pulmonary / diagnosis. Viral Load / methods. World Health Organization. Young Adult


3. Kenyon C, Pillay K, Jacobs P: Castleman's disease and retroviral therapy. Transfus Apher Sci; 2007 Aug;37(1):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Castleman's disease and retroviral therapy.
  • The escalating pandemic of the acquired immunodeficiency disease in sub-Saharan Africa is associated with an increasing incidence of the lymphoproliferative disorders where evidence shows that highly active retroviral therapy can reconstitute immunologic competence and, at least in some groups exemplified by Kaposi's sarcoma, result in an outcome comparable to uninfected controls.
  • Paradoxically other subtypes are less responsive exemplified by Burkitt lymphoma and multicentric Castleman's disease, where they are localised and may present after starting treatment.
  • This association provides a model to test the concept that pathogenesis may reflect an aberrant response to antigens including human herpesvirus-8 thereby renewing focus on proactive inclusion of anti-herpes drugs with conventional treatment for retrovirus particularly prior to initiating chemotherapy.
  • [MeSH-minor] Adult. Africa South of the Sahara. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / pathology. Fatal Outcome. Female. Herpesvirus 8, Human. Humans. Models, Biological. Reverse Transcriptase Inhibitors / administration & dosage. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / pathology. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy. Tuberculosis, Pulmonary / epidemiology. Tuberculosis, Pulmonary / pathology

  • Genetic Alliance. consumer health - Castleman's Disease.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931977.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reverse Transcriptase Inhibitors
  •  go-up   go-down


Advertisement
4. Bryant AE, Genc M, Hurtado RM, Chen KT: Pulmonary Kaposi's sarcoma in pregnancy. Am J Perinatol; 2004 Aug;21(6):355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary Kaposi's sarcoma in pregnancy.
  • Kaposi's sarcoma in human immunodeficiency virus (HIV) -infected women, often misdiagnosed, has an aggressive clinical course, with high rates of visceral involvement and decreased survival.
  • We describe the first case of isolated pulmonary Kaposi's sarcoma in pregnancy.
  • A nulliparous woman was diagnosed with AIDS after presenting at 25 weeks gestation with a cough and multiple pulmonary nodules.
  • Extensive pulmonary evaluation was nondiagnostic until thorascopic lung biopsy revealed Kaposi's sarcoma.
  • Despite combination antiretroviral therapy, her malignancy progressed.
  • She received chemotherapy postpartum and remains in remission.
  • Pulmonary Kaposi's sarcoma should be considered in the differential diagnosis of HIV-infected obstetric patients with respiratory compromise.
  • Definitive diagnosis is necessary given the aggressive clinical course that is potentially responsive to therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lung Neoplasms / diagnosis. Pregnancy Complications, Infectious / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Sarcoma, Kaposi / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pregnancy. Time Factors


5. Rubio ER, Chang EE, Kovitz KL: Thoracoscopic management of pleural effusions in Kaposi's sarcoma: a rapid and effective alternative for diagnosis and treatment. South Med J; 2002 Aug;95(8):919-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracoscopic management of pleural effusions in Kaposi's sarcoma: a rapid and effective alternative for diagnosis and treatment.
  • Kaposi's sarcoma (KS) is one of the most common causes of pleural effusion in patients with acquired immunodeficiency syndrome (AIDS).
  • Their treatment is difficult, and they respond poorly to chemical pleurodesis.
  • Even systemic chemotherapy against KS has little effect on the pleural effusions.
  • Commonly, repeated therapeutic thoracentesis or chest tube drainage is required.
  • [MeSH-major] Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / surgery. Pleurodesis / methods. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / surgery. Thoracoscopy
  • [MeSH-minor] Adult. Humans. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12190232.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Bagnato A, Spinella F, Rosanò L: The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol; 2008 Aug;86(8):473-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.
  • The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ET AR and ET BR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma.
  • At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies.
  • Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Endothelins / genetics. Neoplasms / drug therapy. Neoplasms / genetics
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. Animals. Endothelin-1 / biosynthesis. Humans. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / pathology. Receptors, Endothelin / drug effects. Receptors, Endothelin / genetics. Receptors, Endothelin / physiology. Signal Transduction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758494.001).
  • [ISSN] 0008-4212
  • [Journal-full-title] Canadian journal of physiology and pharmacology
  • [ISO-abbreviation] Can. J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Endothelin-1; 0 / Endothelins; 0 / Receptors, Endothelin
  • [Number-of-references] 87
  •  go-up   go-down


7. Kobayashi M, Takaori-Kondo A, Shindo K, Mizutani C, Ishikawa T, Uchiyama T: Successful treatment with paclitaxel of advanced AIDS-associated Kaposi's sarcoma. Intern Med; 2002 Dec;41(12):1209-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with paclitaxel of advanced AIDS-associated Kaposi's sarcoma.
  • Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumor.
  • We report a 44-year-old Japanese man with advanced AIDS-associated KS, which was spread over bilateral pulmonary parenchyma.
  • He was initially treated with combination chemotherapy with a partial response.
  • Upon the recurrence of his KS two months after the completion of the combination chemotherapy, the patient received paclitaxel, which brought about a complete response.
  • Highly active antiretrovial therapy (HAART) was initiated three months before the combination chemotherapy, and the CD4+ T-cell count had risen before starting paclitaxel.
  • His dinical course suggests that paclitaxel was highly effective for KS disease control as previously reported, and that immune restoration with HAART is crucial in the treatment of KS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Agents, Phytogenic / therapeutic use. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Humans. Male. Treatment Outcome


8. Aboulafia DM: The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest; 2000 Apr;117(4):1128-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma.
  • AIDS-related Kaposi's sarcoma (KS) occurs principally in homosexual or bisexual men infected with the newly identified human herpes virus-8, also called KS-associated herpes virus.
  • KS may also occur in the lung, commonly in the setting of extensive mucocutaneous disease and very rarely as an isolated event.
  • Before the advent of highly active antiretroviral therapy (HAART), pulmonary KS had been reported in approximately 10% of patients with AIDS, 25% of patients with cutaneous KS, and in roughly 50% of postmortem examinations of patients with AIDS, KS, and respiratory infections.
  • Pulmonary KS may cause radiographic infiltrates and respiratory symptoms that mimic a variety of other infectious and neoplastic processes.
  • An aggressive diagnostic evaluation of patients who have this condition is essential because chemotherapy and radiation therapy may provide significant palliation, particularly if used in conjunction with HAART.
  • The pathology and pathogenesis of KS is also reviewed, along with the clinical and radiographic presentation, diagnosis, and management of pulmonary KS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Herpesvirus 8, Human. Lung Neoplasms. Sarcoma, Kaposi


10. Sekiya N, Imamura A: [Doxil--pegylated liposomal doxorubicin]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1439-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi's sarcoma.
  • The characteristics of PLD are reduction of the severe side effects of cardiac toxicity and myelosuppression seen with doxorubicin, and a higher anti-tumor effect from the selective high maintenance of the drug concentration in the tumor tissue.
  • This does not mean, however, that PLD should be used in the treatment of all patients with Kaposi's sarcoma; in some cases with skin lesions only and local distribution highly active antiretroviral therapy (HAART) alone is effective.
  • While precise criteria for the use of PLD have not been determined, it is used in combination with HAART in patients with rapid progression, edema or strong pain, pulmonary complications, or extensive organ complications, or in cases when tumor progression is not slowed with HAART alone.
  • Common side effects are myelosuppression and digestive symptoms, but when combined with HAART these complications do not become serious enough to lead to a discontinuation of treatment.
  • The advantages of using PLD are less myelosuppression, less drug interaction, and the possibility of switching to outpatient administration.
  • The level of treatment safety, tolerability, and treatment effectiveness makes it possible to investigate vigorous concomitant use with HAART, and expanded indications to other solid tumors may be expected.
  • [MeSH-major] Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Polyethylene Glycols / therapeutic use
  • [MeSH-minor] Adult. Clinical Trials as Topic. Female. Humans. Male. Middle Aged. Sarcoma, Kaposi / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701868.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A: Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol; 2001 Sep 15;19(18):3848-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy.
  • PURPOSE: Kaposi's sarcoma (KS) is the most common AIDS-related malignancy.
  • Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months.
  • We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.
  • The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.
  • RESULTS: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART.
  • Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69).
  • CONCLUSION: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lung Neoplasms / complications. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Ethnic Groups. Humans. Middle Aged. Multivariate Analysis. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome


12. Krayem AB, Abdullah LS, Raweily EA, Wali SO, Rawas MM, Samman YS, Batouk AA: The diagnostic challenge of pulmonary Kaposi's sarcoma with pulmonary tuberculosis in a renal transplant recipient: a case report. Transplantation; 2001 May 27;71(10):1488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic challenge of pulmonary Kaposi's sarcoma with pulmonary tuberculosis in a renal transplant recipient: a case report.
  • We report a case of a 39-year-old, HIV-negative, post renal transplant patient who developed mucocutaneous Kaposi's sarcoma with lung parenchymal involvement and concurrently culture proven pulmonary tuberculosis.
  • To the best of our knowledge, this is the first case report of this combination, which presented with cavitating lung nodules and responded well to withdrawal of immunosuppressive drugs beside antituberculous treatment.
  • [MeSH-major] Kidney Transplantation. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Drug Therapy, Combination. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Radiography, Thoracic. Tomography, X-Ray Computed


13. Bagnato A, Rosanò L: The endothelin axis in cancer. Int J Biochem Cell Biol; 2008;40(8):1443-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endothelin-1 participates in the growth and progression of a variety of tumors such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, bladder, endometrial carcinomas, Kaposi's sarcoma, brain tumors, melanoma, and bone metastases.
  • This review highlights key signaling pathways activated by endothelin-1 axis in cancer, since the understanding the full spectrum activated by endothelin-1 is critical for the optimal design of targeted therapies.
  • Preliminary experimental and clinical data demonstrate that interfering with endothelin receptor by using endothelin-1 receptor antagonists alone and in combination with cytotoxic drugs or molecular inhibitors could represent a new mechanism-based antitumor strategy.
  • [MeSH-minor] Cell Proliferation / drug effects. Cell Survival / drug effects. Cell Survival / physiology. Endothelin Receptor Antagonists. Female. GTP-Binding Proteins / physiology. Humans. Male. Neoplasm Invasiveness / physiopathology. Neovascularization, Pathologic / physiopathology. Osteogenesis / physiology. Ovarian Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy. Receptor, Endothelin A / physiology. Receptor, Epidermal Growth Factor / physiology. Signal Transduction

  • Guide to Pharmacology. gene/protein/disease-specific - Endothelin receptors - overview and references .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325824.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin Receptor Antagonists; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptors, Endothelin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.1.- / GTP-Binding Proteins
  • [Number-of-references] 27
  •  go-up   go-down


14. Colebunders R, Bastian I: A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis; 2000 Feb;4(2):97-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis.
  • Recommendations on the management of smear-negative pulmonary tuberculosis (TB) are still based on the behaviour of this disease in populations unaffected by the human immunodeficiency virus (HIV).
  • Studies prior to the HIV epidemic estimated that there were 1.22 cases of smear-negative and extra-pulmonary TB for each smear-positive case.
  • Patients with smear-negative pulmonary TB were found to be less infectious and to have a lower mortality, but a significant proportion (50%-71%) progressed to active disease justifying treatment.
  • Moreover, a wide variety of regimens also proved effective in the treatment of smear-negative disease in HIV-negative patients.
  • While apparently remaining less infectious than smear-positive cases, HIV-positive patients with smear-negative pulmonary TB are generally more immunocompromised, have more adverse drug reactions, and suffer higher mortality rates on treatment.
  • Clinical decision-making has also been complicated because HIV co-infection broadens the differential diagnoses of smear-negative pulmonary TB to include diseases such as Pneumocystis carinii pneumonia (PCP), pulmonary Kaposi's sarcoma, and Gram-negative bacteraemia.
  • Our approach to smear-negative pulmonary TB must therefore adapt to these changed parameters.
  • Management algorithms based on several features (clinical symptoms, response to antibiotic trials, smear investigations, and chest radiography) have been developed to improve case detection.
  • National tuberculosis programmes should also consider extending the use of rifampicin-based short-course chemotherapy (SCC) to new patients with smear-negative disease.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. Sputum / microbiology. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / drug therapy
  • [MeSH-minor] Antitubercular Agents / administration & dosage. Belgium / epidemiology. Diagnosis, Differential. Disease Outbreaks / prevention & control. Female. Humans. Incidence. Male. Risk Factors. Survival Rate


15. Leidner RS, Aboulafia DM: Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS; 2005 Oct;19(10):635-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome.
  • The objective of this case series and literature review is to characterize the clinical course and prognosis of HIV-infected patients with Kaposi's sarcoma (KS) flare during immune reconstitution inflammatory syndrome (IRIS), a heterogeneous and sometimes fatal disorder of immune perturbation after initiation of highly active antiretroviral therapy (HAART).
  • In our single institution series, mean time to onset of KS flare was 5 weeks.
  • Six fatalities are reported, 4 from pulmonary KS and 2 from unrelated causes.
  • Systemic chemotherapy universally led to tumor regression, but was administered in only 10 of 19 cases.
  • Even for those patients with rapidly symptomatic KS, early systemic chemotherapy is effective in suppressing IRIS-associated flare.
  • Particular vigilance is recommended for pulmonary involvement.
  • [MeSH-major] AIDS-Related Opportunistic Infections / immunology. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Inflammation. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / immunology
  • [MeSH-minor] Adult. Disease Progression. HIV-1 / drug effects. Humans. Male. Syndrome


16. Chandan K, Madnani N, Desai D, Deshpande R: AIDS-associated Kaposi's sarcoma in a heterosexual male--a case report. Dermatol Online J; 2002 Oct;8(2):19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated Kaposi's sarcoma in a heterosexual male--a case report.
  • Biopsies from multiple lesions confirmed the diagnosis of Kaposi's sarcoma.
  • He subsequently developed pulmonary and peritoneal effusions and died 3 months later of cardiopulmonary arrest.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heterosexuality. Sarcoma, Kaposi / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. Adult. Fatal Outcome. Humans. Male


17. Davis JL, Shum AK, Huang L: A 36-year-old man with AIDS and relapsing, nonproductive cough. Chest; 2007 Jun;131(6):1929-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rapidly progressive, fatal recrudescence of pulmonary Kaposi sarcoma developed in an HIV-infected man who was receiving corticosteroids for treatment of an immune reconstitution syndrome secondary to Mycobacterium avium complex pulmonary infection.
  • We discuss the implications for current diagnosis and management of HIV-associated pulmonary diseases.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Acquired Immunodeficiency Syndrome / complications. Mycobacterium avium-intracellulare Infection / complications. Mycobacterium avium-intracellulare Infection / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / adverse effects. Adrenal Cortex Hormones / therapeutic use. Adult. Anti-Retroviral Agents / adverse effects. Anti-Retroviral Agents / therapeutic use. Cough / etiology. Fatal Outcome. Humans. Lung / microbiology. Lung / pathology. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Male. Mycobacterium avium Complex / pathogenicity. Recurrence. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / drug therapy






Advertisement